Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GRAIL, Inc. (Nasdaq: GRAL) files reports with the U.S. Securities and Exchange Commission that provide detail on its operations as a healthcare diagnostics company focused on multi-cancer early detection. On this page, you can review GRAIL’s SEC filings, including current reports on Form 8-K that describe material events such as private placements, equity distribution agreements, commercial leases, preliminary financial results, and strategic collaboration arrangements.
Recent 8-K filings outline securities purchase agreements for private placements of common stock and pre-funded warrants, a stock purchase agreement with Samsung-related entities tied to a planned business collaboration for commercialization of the Galleri test in Asia, and an equity distribution agreement that allows at-the-market offerings of common stock through designated sales agents. Other filings describe a long-term lease for a new corporate headquarters in Sunnyvale, California and the release of quarterly financial results, along with the company’s use of non-GAAP measures such as Adjusted Gross Profit (Loss) and Adjusted EBITDA.
Through these filings, investors can see how GRAIL structures its financings, the key terms of its strategic agreements, and selected information about its financial condition and operations. Stock Titan’s platform adds AI-powered summaries that explain the main points of each filing in plain language, highlight important sections, and help distinguish between one-time transactions and ongoing obligations. Users can also quickly locate information related to equity issuances, registration rights, and other matters that may affect existing or prospective shareholders.
This Schedule 13G/A reports that PRIMECAP MANAGEMENT CO/CA beneficially owns 2,057,089 shares of GRAIL common stock (class reported as COM), representing 5.72% of the outstanding class. The filing discloses sole voting power over 2,027,466 shares and sole dispositive power over 2,057,089 shares.
The statement affirms the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Items identifying group members, subsidiaries and related classifications are marked not applicable, and the filing includes the certification required under Item 10 attesting to the accuracy of the disclosure.
GRAIL, Inc. (GRAL) reported Q2 2025 results showing revenue growth and materially smaller operating losses versus prior-year periods after large pushdown impairments in 2024. Total revenue was $35.5 million for the quarter and $67.4 million for the six months, driven mainly by screening revenue. Net loss was $114.0 million for the quarter and $220.2 million for six months, versus multi‑hundred‑million and billion‑level losses in 2024 primarily from goodwill and IPR&D impairments. The balance sheet shows $130.8 million of cash and restricted cash and $475.3 million of short‑term marketable securities; management believes these resources are sufficient to fund operations for at least 12 months. The company completed its Spin‑Off from Illumina, received $932.3 million of disposal funding subject to a time‑limited clawback, and disclosed positive registrational trial signals (NHS‑Galleri prevalent round and initial PATHFINDER 2 top‑line results). Significant amortization and prior impairment charges continue to affect reported operating results and accumulated deficit.
GRAIL, Inc. furnished a press release reporting its financial results for the second quarter ended June 30, 2025; the press release is attached as Exhibit 99.1 to this current report. The 8-K text states the press release announces second-quarter financial results but does not include the underlying financial tables or metrics within the filing itself.
The exhibit is furnished, not filed, so the press release is not automatically incorporated by reference into other SEC filings unless explicitly stated. The report also identifies the company as an emerging growth company and confirms its common stock (par value $0.001) trades under the symbol GRAL on the Nasdaq Global Select Market. Readers must consult Exhibit 99.1 for the full financial figures and management commentary.